DRAXIS Acquires Canadian Rights to 8 Elan Neurology Products

August 1999
Worldwide Biotech;Aug99, Vol. 11 Issue 8, p2
Trade Publication
Reports that Draxis Health Inc. has in-licensed from Elan Corp. PLC the exclusive Canadian rights to eight neurology products. Conditions under the agreement; Task of Draxis Pharmaceutica; Comments from officials of both companies.


Related Articles

  • Product Summaries.  // Worldwide Biotech;Aug99, Vol. 11 Issue 8, p3 

    Presents information on the neurology products being marketed by Draxis Health Inc. in Canada. Mechanism of action of Zanaflex; Diastat; Mysoline.

  • Elan Digs Out from Under. Houlton, Sarah // Pharmaceutical Executive;Dec2002, Vol. 22 Issue 12, p22 

    Assesses the decline of 2002 third quarter earnings of pharmaceutical company, Elan Corp. in the U.S. Licensing agreement between Elan Corp. and Watson Pharmaceuticals Inc. on the marketing of nifedipine; Generic competition of Zanaflex; Decline of investments in the biotechnology companies.

  • OTHER NEWS TO NOTE.  // BioWorld Today;8/23/2007, Vol. 18 Issue 164, p2 

    This section offers news briefs on the pharmaceutical industry. Alfacell Corp. reported that Onconase decreases reactive oxygen intermediates (ROI) in normal cell types and tumor cell lines. Biogen Idec Inc. and Elan Corp. Plc reported that the National Institute for Health and Clinical...

  • Curis and Elan conclude neurology joint venture.  // PharmaWatch: CNS;July 2003, Vol. 2 Issue 7, p12 

    Focuses on the terms of the agreement signed between Curis Inc. and Elan Corp. in the U.S. Development of small molecule drugs; Treatment of the patients with nervous system disorders; Increase on the number of distributors.

  • OTHER NEWS TO NOTE.  // BioWorld International;12/16/2009, Vol. 14 Issue 50, p2 

    This section offers news briefs related to biotechnology. Diurnal Ltd. has raised 300,000 British pounds with a further 300,000 British pounds invested by Finance Wales which will allow it to complete Phase I trials of its hydrocortisone. The Japanese Ministry of Health, Labor and Welfare has...

  • Elan: realigning its CNS franchise.  // PharmaWatch: CNS;May 2004, Vol. 3 Issue 5, p4 

    Reports that Elan Corp. PLC has sold its rights to Zonegran and Frova drugs to Eisai Co. Ltd. and Vernalis Group Inc. in Ireland. Impact of the drugs' sale on improving its profitability; Amount expected by the company to be generated by its novel immunosuppressant drugs; Concentration of Elan...

  • Generics Watch.  // Drug Store News;12/13/99, Vol. 21 Issue 20, p54 

    Presents articles pertaining to generics in the United States. Decision of the Senate Judiciary Committee in postponing consideration of the `Drug Patent Term Restoration Review Procedure Act'; Licensing agreement between Schein Pharmaceutical and Elan Corp. PLC; Move of the Food and Drug...

  • OTHER NEWS TO NOTE.  // BioWorld International;3/14/2007, Vol. 12 Issue 11, p5 

    The article offers news briefs on the international biotechnology industry. Active Biotech reported positive results from a Phase 1b study of an oral agent being developed to treat prostate cancer. Amarin Corp. acquired rights to develop and market a nasal lorazepam formulation that was...

  • Current Treatment Approaches for Neoplastic Meningitis: Nursing Management of Patients Receiving Intrathecal DepoCyt{supTM]. Craig, Catherine // Oncology Nursing Forum;Sep2000, Vol. 27 Issue 8, p1225 

    Discusses neoplastic meningitis and the nursing implications for the intrathecal administration of chemotherapy. Signs and symptoms of neoplastic meningitis; Diagnosis; Treatment.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics